image: LGK974 treatment reduces tibial trabecular bone morphometric parameters in Sost-/- mice. a Colour coded (heat map of trabecular bone thickness), representative 3D µCT images of the proximal region of loaded male and female tibiae (male and female) treated with vehicle and LGK974. Representative 2D µCT cross sections of the proximal region of loaded tibiae are also shown. b Trabecular thickness heat maps of the proximal end of non-loaded tibiae (male and female) treated with vehicle control and LGK974. Representative 2D µCT cross sections of non-loaded tibiae are also shown. c Representative image of a Sost-/- mouse tibia, with a black rectangle indicating the analysed region. Effect of LGK974 on trabecular (d, e) bone and tissue volume (BV and TV), and (f) bone area (B.Ar) of Sost-/- male non-loaded and loaded tibiae. g–i Effect of LGK974 on the same cortical parameters of female tibiae. Representative images of alizarin red (days 4 and 11) and calcein green (days 18 and 25) labelled tibial cortical bone surfaces of male (j) control and (k) LGK974 treated Sost-/- mice. l Percentage mineral surface (MS/BS) and (m) bone formation rate (BFR/BS) of control and LGK974 treated male loaded tibia (alizarin red dual labelled). n Percentage mineral surface (MS/BS) and (o) bone formation rate (BFR/BS) of control and LGK974 treated male loaded tibia (calcein green dual labelled). Line graphs (f, i) represent means ± SEM (1 = non-loaded control (dark blue); 2 = non-loaded LGK974 treated (light blue); 3 = loaded control (maroon); 4 = loaded LGK974 treated (red)). Graphical heat maps below line graphs summarise statistical differences of the above groups 1-4 at specific matched locations along the length of the analysed region and represent the overall effect of LGK974 treatment (dark blue P ≥ 0.05, blue 0.01 ≤ P < 0.05, green 0.001 ≤ P < 0.01, yellow P < 0.001). Interaction is between LGK974 treatment and loading. For violin plots, means of each group are indicated by the solid line, and upper and lower dashed lines represent quartiles. Blue and red represent vehicle controls and LGK974 treated groups, respectively. *P ≤ 0.05, **P ≤ 0.01 and ****P ≤ 0.000 1. Group sizes were n = 5 treated females, n = 6 control females, n = 4 treated males and n = 5 control males. Dynamic histomorphometry group sizes were n = 4 control and n = 4 treated males, with two levels analysed for each tibia.
Credit: Bone Research
Sclerosteosis is a rare genetic disorder that causes excessive bone growth, leading to life-altering complications, including hearing loss and facial paralysis. In a promising new breakthrough, researchers have identified a drug called LGK974, which targets the Wnt signaling pathway by inhibiting the enzyme Porcupine. This treatment has shown the potential to effectively reduce bone mass and prevent further skeletal overgrowth in mice, offering hope for those suffering from this debilitating condition. Unlike the high-risk surgeries traditionally used to manage sclerosteosis, LGK974 presents a non-invasive alternative that could dramatically improve patient quality of life.
Sclerosteosis arises from mutations in the SOST gene, causing abnormally high bone mass and skeletal overgrowth, which can lead to severe health issues such as hearing loss and increased intracranial pressure. The key culprit behind this condition is the disruption of the Wnt signaling pathway, crucial for bone development. This groundbreaking study seeks to determine whether inhibiting Porcupine, a key regulator within this pathway, can reverse the bone overgrowth seen in this rare and serious disorder.
This study was published (DOI: 10.1038/s41413-025-00406-3) on April 7 2025 in Bone Research, by a research team from the Skeletal Biology Group at the Royal Veterinary College, London, in collaboration with UCB Pharma, Slough, UK. Led by Dr. Scott J. Roberts, the team investigates the impact of LGK974, a Porcupine inhibitor, on bone mass regulation in a sclerosteosis mouse model. By targeting the Wnt signaling pathway, LGK974 offers an innovative approach to combat the excessive bone growth seen in sclerosteosis. The research uncovers the potential of LGK974 as a promising treatment for this ultra-rare condition, providing an alternative to invasive surgeries commonly required for severe cases.
Through both in vitro and in vivo experiments, the research team examined how LGK974 affects bone formation and the Wnt/β-catenin signaling pathway. The results were striking: LGK974 inhibited osteoblast activity and mineralization, mimicking the effects of sclerostin, a natural bone growth regulator. The drug successfully reduced excessive bone growth in the skull, vertebrae, and tibiae of Sost-/- mice, a model of sclerosteosis. Intriguingly, the drug exhibited a potential sexual dimorphic response, with male mice showing more pronounced benefits. The study also suggests that LGK974 not only prevents bone overgrowth but also preserves bone structure, reducing ossification. The potential for LGK974 to address the dangerous symptoms of sclerosteosis—such as hearing loss and intracranial pressure—could offer a significant improvement over the current surgical options available to patients.
"The ability to effectively inhibit bone overgrowth at sites of severe/fatal sclerosteosis pathologies, without obviously disrupting other physiological functions, is a monumental step forward," said Dr. Scott J. Roberts, a senior researcher in the study. "The success of LGK974 in preclinical models marks a significant breakthrough, moving us closer to a viable, non-invasive treatment that could offer real relief for patients with this devastating condition."
The findings of this study hold great promise not only for sclerosteosis but also for other Wnt-related high bone mass conditions, such as Van Buchem disease. Targeting Porcupine provides a new avenue for treatment that could reduce reliance on high-risk surgeries. However, further clinical trials are necessary to confirm the drug’s safety and efficacy in humans, with attention to possible sex-based differences in response. This research highlights the importance of developing alternative, targeted therapies to manage bone overgrowth and improve the lives of patients who currently face limited treatment options and a lifetime of pain, discomfort and debilitating symptoms.
###
References
DOI
Original Source URL
https://doi.org/10.1038/s41413-025-00406-3
Funding Information
Funding from UCB Pharma.
About Bone Research
Bone Research was founded in 2013. As a new English-language periodical, Bone Research focuses on basic and clinical aspects of bone biology, pathophysiology and regeneration, and supports the foremost discoveries resulting from basic investigations and clinical research related to bone. The aim of the Journal is to foster the worldwide dissemination of research in bone-related physiology, pathology, diseases and treatment.
Journal
Bone Research
Subject of Research
Not applicable
Article Title
Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies
Article Publication Date
7-Apr-2025
COI Statement
The authors declare that they have no competing interests.